Echo IQ reports positive results from EchoSolv trial to identify severe aortic stenosis

Go to Imelda Cotton author's page
By Imelda Cotton - 
Echo IQ ASX EIQ EchoSolv trial severe aortic stenosis AS St Vincent’s Hospital Melbourne

In the clinical trial at St Vincent’s Hospital in Melbourne, interim results show EchoSolv successfully identified 100% of patients with severe AS within current clinical guidelines.


Medical technology company Echo IQ (ASX: EIQ) has released positive interim results from a clinical trial demonstrating the artificial intelligence of its EchoSolv technology for the identification of severe aortic stenosis (AS).

The trial was conducted at St Vincent’s Hospital in Melbourne with the aim of evaluating whether the innovative decision-making platform could enhance the identification of severe AS and help guide doctors to make active management plans for patients.

Retrospective trial

EchoSolv was applied retrospectively to echocardiography data from the hospital and the results were compared with cardiologist reports and patient clinical outcomes.

The technology successfully identified 100% of patients with guideline-defined severe AS, which was 317 patients or 3.8% of the study population of 8,257 patients.

Approximately 142 (or 45%) of those patients had not previously been identified by a cardiologist as having the condition.

The trial identified an additional 145 patients (or 1.8% of the total study population) with a medium-to-high probability of developing severe AS who fall outside current clinical practice guidelines for a diagnosis.

Support role

Echo IQ’s trial demonstrated the potential for EchoSolv to play an important support role in echocardiogram reporting and valve intervention decisions.

In the group of patients identified with severe AS, 57% of patients went on to receive aortic valve replacements.

For patients who had not initially been identified as having severe AS, only 23% underwent valve intervention.

Saving lives

Echo IQ chief medical advisor Professor David Playford said the interim findings represented a step towards the company’s goal of saving lives by assisting doctors in identifying cases of heart valve disease.

“Severe AS is a serious condition with a high risk of death if left untreated, so identifying all patients is of great importance,” he said.

“We expect the automatic highlighting of patients with the AS phenotype using EchoSolv will assist doctors in decision-making for aortic valve intervention and follow-up in a highly consistent, systematic and efficient manner.”

Full results of the study will be released following the analysis of a further 42 echocardiogram reports and the completion of a clinical study St Vincent’s sister hospital in Sydney.